Integrating Lung Physiology, Immunology, and Tuberculosis

Trends in Microbiology

Volumn 25, Issue 8, 2017, Pages 688-697

  Torrelles, Jordi B ^a   Schlesinger, Larry S ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

airborne infection; mucosal immunity; Mycobacterium tuberculosis; respiratory track; tuberculosis

Indexed keywords

COMPLEMENT COMPONENT C3; CORD FACTOR; INTERLEUKIN 8; LIPOARABINOMANNAN; MANNOSE; MANNOSE RECEPTOR; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D;

BACTERIAL TRANSMISSION; EPITHELIAL LINING FLUID; HUMAN; IMMUNOLOGY; LATENT TUBERCULOSIS; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; LUNG TUBERCULOSIS; MUCOSAL-ASSOCIATED INVARIANT T CELL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; REVIEW; ANIMAL; CELLULAR IMMUNITY; HOST PATHOGEN INTERACTION; LUNG; MICROBIOLOGY; MOUSE; MUCOSAL IMMUNITY; PATHOGENICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RESPIRATORY SYSTEM; TRANSMISSION;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; LUNG; MICE; MYCOBACTERIUM TUBERCULOSIS; RESPIRATORY SYSTEM; TUBERCULOSIS, PULMONARY;

EID: 85016487979     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2017.03.007     Document Type: Review

References (100)

1. Kulkarni, P., et al. Fundamentals of single particle transport. Kulkarni, P., et al. (eds.) Aerosol measurement: principles, techniques, and applications, 2001, Wiley, 15–30.
2. Heyder, J., et al. Biological variability of particle deposition in the human respiratory tract during controlled and spontaneous mouth-breathing. Ann. Occup. Hyg. 26 (1982), 137–147.
3. Fernandez, T.A., Casan, C.P., Deposition of inhaled particles in the lungs. Arch. Bronconeumol. 48 (2012), 240–246.
4. Espinoza, C.G., et al. Laryngeal tuberculosis. Laryngoscope 91 (1981), 110–113.
5. Arnett, E., et al. Host pathogen biology for airborne Mycobacterium tuberculosis. Hickey, A., (eds.) Drug Delivery Systems for Tuberculosis Preveniton and Treatment, 2016, John Wiley, 11–47.
6. Nicod, L.P., Lung defenses: An overview. Eur. Resp. Rev. 14 (2005), 45–50.
7. Flynn, J.L., Chan, J., Immunology of tuberculosis. Annu. Rev. Immunol. 19 (2001), 93–129.
8. Guirado, E., et al. Macrophages in tuberculosis: friend or foe. Semin. Immunopathol. 35 (2013), 563–583.
9. Heyder, J., Alveolar deposition of inhaled particles in humans. Am. Ind. Hyg. Assoc. J. 43 (1982), 864–866.
10. Heyder, J., Particle transport onto human airway surfaces. Eur. J. Respir. Dis. 119:Suppl (1982), 29–50.
11. Mercer, R.R., et al. Cell number and distribution in human and rat airways. Am. J. Respir. Cell. Mol. Biol. 10 (1994), 613–624.
12. Rock, J.R., et al. Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling. Dis. Model Mech. 3 (2010), 545–556.
13. Atkinson, J.J., et al. Clara cell adhesion and migration to extracellular matrix. Respir. Res., 9, 2008, 1.
14. Li, F., et al. The defect in autophagy induction by clinical isolates of Mycobacterium tuberculosis is correlated with poor tuberculosis outcomes. PLoS ONE, 11, 2016, e0147810.
15. Jick, S.S., et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 55 (2006), 19–26.
16. Barboza, C.E., et al. Tuberculosis and silicosis: epidemiology, diagnosis and chemoprophylaxis. J. Bras. Pneumol. 34 (2008), 959–966.
17. Davies, P.D., et al. Smoking and tuberculosis: the epidemiological association and immunopathogenesis. Trans. R. Soc. Trop. Med. Hyg. 100 (2006), 291–298.
18. Behr, M.A., Waters, W.R., Is tuberculosis a lymphatic disease with a pulmonary portal?. Lancet Infect. Dis. 14 (2014), 250–255.
19. Nair, V.R., et al. Microfold cells actively translocate Mycobacterium tuberculosis to initiate infection. Cell Rep. 16 (2016), 1253–1258.
20. Teitelbaum, R., et al. The M cell as a portal of entry to the lung for the bacterial pathogen Mycobacterium tuberculosis. Immunity 10 (1999), 641–650.
21. Pankow, W., von Wichert, P., M cell in the immune system of the lung. Respiration 54 (1988), 209–219.
22. Rivas-Santiago, B., The potential role of lung epithelial cells and beta-defensins in experimental latent tuberculosis. Scand. J. Immunol. 67 (2008), 448–452.
23. Harriff, M.J., et al. Human lung epithelial cells contain Mycobacterium tuberculosis in a late endosomal vacuole and are efficiently recognized by CD8(+) T cells. PLoS ONE, 9, 2014, e97515.
24. Gold, M.C., et al. MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis. Immunol. Rev. 264 (2015), 154–166.
25. Jiang, J., et al. Enhanced immune response of MAIT cells in tuberculous pleural effusions depends on cytokine signaling. Sci. Rep., 6, 2016, 32320.
26. Ochs, M., et al. The number of alveoli in the human lung. Am. J. Respir. Crit. Care Med. 169 (2004), 120–124.
27. Stone, K.C., et al. Distribution of lung cell numbers and volumes between alveolar and nonalveolar tissue. Am. Rev. Respir. Dis. 146 (1992), 454–456.
28. Torrelles, J.B., et al. Role of C-type lectins in mycobacterial infections. Curr. Drug Targets 9 (2008), 102–112.
29. Carlson, T.K., et al. Pulmonary innate immunity: soluble and cellular host defenses of the lung. Marsh, C., (eds.) Regulation of Innate Immune Function, 2010, Transworld Research Network, 165–211.
30. Arcos, J., et al. Human lung hydrolases delineate Mycobacterium tuberculosis-macrophage interactions and the capacity to control infection. J. Immunol. 187 (2011), 372–381.
31. Arcos, J., et al. Lung mucosa lining fluid modifies Mycobacterium tuberculosis to reprogram human neutrophil killing mechanisms. J. Infect. Dis. 212 (2015), 948–958.
32. Arcos, J., et al. Mycobacterium tuberculosis cell wall released fragments by the action of the human lung mucosa modulate macrophages to control infection in an IL-10-dependent manner. Mucosal Immunol., 2017 mi2016115 [pii].
33. Mason, R.J., Biology of alveolar type II cells. Respirology 11:Suppl (2006), S12–S15.
34. Hook, G.E., Gilmore, L.B., Hydrolases of pulmonary lysosomes and lamellar bodies. J. Biol. Chem. 257 (1982), 9211–9220.
35. Torrelles, J.B., Broadening our view about the role of Mycobacterium tuberculosis cell envelope components during infection: a battle for survival. Cardona, P.J., (eds.) Understanding Tuberculosis – Analyzing the Origin of Mycobacterium tuberculosis Pathogenicity, 2012, Intech, 77–122.
36. Kang, P.B., et al. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J. Exp. Med. 202 (2005), 987–999.
37. Ferguson, J.S., et al. Surfactant protein D binds to Mycobacterium tuberculosis bacili and lipoarabinomannan via carbohydrate–lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages. J. Immunol. 163 (1999), 312–321.
38. Ferguson, J.S., et al. Surfactant protein D increases fusion of Mycobacterium tuberculosis-containing phagosomes with lysosomes in human macrophages. Infect. Immun. 74 (2006), 7005–7009.
39. Bolger, M.S., et al. Complement levels and activity in the normal and LPS-injured lung. Am. J. Physiol. Lung Cell Mol. Physiol. 292 (2007), L748–L759.
40. Schlesinger, L.S., Mycobacterium tuberculosis and the complement system. Trends Microbiol. 6 (1998), 47–49.
41. Ferguson, J.S., et al. Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid. Infect. Immun. 72 (2004), 2564–2573.
42. Chandler, M.J., Levels and specificity of antibody in bronchoalveolar lavage (BAL) and serum in an animal model of trimellitic anhydride-induced lung injury. J. Allergy Clin. Immunol. 80 (1987), 223–229.
43. Shigemura, M., et al. Levels of transferrin in bronchoalveolar lavage fluid in sarcoidosis. Lung 188 (2010), 151–157.
44. Singh, P.K., et al. Production of beta-defensins by human airway epithelia. Proc. Natl. Acad. Sci. U.S.A. 95 (1998), 14961–14966.
45. Bicer, E., et al. Characterizing the composition of human respiratory tract lining fluids in health and disease. Am. J. Respir. Crit. Care Med., 2012 A4661.
46. Cantin, A.M., et al. Normal alveolar epithelial lining fluid contains high levels of glutathione. J. Appl. Physiol. 63 (1987), 152–157.
47. Madebo, T., et al. Circulating antioxidants and lipid peroxidation products in untreated tuberculosis patients in Ethiopia. Am. J. Clin. Nutr. 78 (2003), 117–122.
48. Reddy, Y.N., et al. Role of free radicals and antioxidants in tuberculosis patients. Indian J. Tuberc. 51 (2003), 213–218.
49. van Golde, L.M., Synthesis of surfactant lipids in the adult lung. Annu. Rev. Physiol. 47 (1985), 765–774.
50. Veldhuizen, R., et al. The role of lipids in pulmonary surfactant. Biochim. Biophys. Acta 1408 (1998), 90–108.
51. Wright, J.R., Immunomodulatory functions of surfactant. Physiol. Rev. 77 (1997), 931–962.
52. Reid, K.B., et al. Surfactant and lung inflammation. Thorax 60 (2005), 620–622.
53. Yu, S.H., Possmayer, F., Effect of pulmonary surfactant protein A and neutral lipid on accretion and organization of dipalmitoylphosphatidylcholine in surface films. J. Lipid Res. 37 (1996), 1278–1288.
54. Abate, W., et al. Surfactant lipids regulate LPS-induced interleukin-8 production in A549 lung epithelial cells by inhibiting translocation of TLR4 into lipid raft domains. J. Lipid Res. 51 (2010), 334–344.
55. Kazachkov, M.Y., et al. Lipid-laden macrophage index and inflammation in bronchoalveolar lavage fluids in children. Eur. Respir. J. 18 (2001), 790–795.
56. Gibeon, D., et al. Lipid-laden bronchoalveolar macrophages in asthma and chronic cough. Respir. Med. 108 (2014), 71–77.
57. Dragomir, A., et al. Superinfection with Mycobacterium tubercuosis in a patient with pulmonary alveolar proteinosis. Maedica J. Clin. Med. 3 (2008), 59–63.
58. Dodd, C.E., et al. CD36-mediated uptake of surfactant lipids by human macrophages promotes intracellular growth of Mycobacterium tuberculosis. J. Immunol. 197 (2016), 4727–4735.
59. Jonsson, S., et al. Human alveolar lining material and antibacterial defenses. Am. Rev. Respir. Dis. 133 (1986), 136–140.
60. Lohmann-Matthes, M.L., Pulmonary macrophages. Eur. Respir. J. 7 (1994), 1678–1689.
61. Hussell, T., Bell, T.J., Alveolar macrophages: plasticity in a tissue-specific context. Nat. Rev. Immunol. 14 (2014), 81–93.
62. Fels, A., Cohn, Z.A., The alveolar macrophage. J. Appl. Physiol. 60 (1986), 353–369.
63. Day, J., et al. Modeling the immune rheostat of macrophages in the lung in response to infection. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 11246–11251.
64. Gleeson, L.E., et al. Cutting Edge: Mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication. J. Immunol. 196 (2016), 2444–2449.
65. Scordo, J.M., et al. Alveolar epithelial cells in Mycobacterium tuberculosis infection: active players or innocent bystanders?. J. Innate Immun. 8 (2016), 3–14.
66. McDonough, K.A., Kress, Y., Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect. Immun. 63 (1995), 4802–4811.
67. Dobos, K.M., et al. Necrosis of lung epithelial cells during infection with Mycobacterium tuberculosis is preceded by cell permeation. Infect. Immun. 68 (2000), 6300–6310.
68. Cai, Y., et al. In vivo characterization of alveolar and interstitial lung macrophages in rhesus macaques: implications for understanding lung disease in humans. J. Immunol. 192 (2014), 2821–2829.
69. Guilliams, M., et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 210 (2013), 1977–1992.
70. Lowe, D.M., et al. Neutrophils in tuberculosis: friend or foe?. Trends Immunol. 33 (2012), 14–25.
71. Brown, A.E., et al. Capacity of human neutrophils to kill Mycobacterium tuberculosis. J. Infect. Dis. 156 (1987), 985–989.
72. Jones, G.S., et al. Killing of Mycobacterium tuberculosis by neutrophils: a nonoxidative process. J. Infect. Dis. 162 (1990), 700–704.
73. Khader, S.A., et al. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J. Immunol. 187 (2011), 5402–5407.
74. Orme, I.M., Basaraba, R.J., The formation of the granuloma in tuberculosis infection. Semin. Immunol. 26 (2014), 601–609.
75. Lin, P.L., et al. PET CT identifies reactivation risk in Cynomolgus macaques with latent M. tuberculosis. PLoS Pathog., 12, 2016, e1005739.
76. Sasindran, J., Torrelles, J.B., Mycobacterium tuberculosis infection and inflammation: what is beneficial for the host and for the bacterium?. Front. Microbiol. 2 (2011), 1–16.
77. Guirado, E., Schlesinger, L.S., Modeling the Mycobacterium tuberculosis Granuloma – the Critical Battlefield in Host Immunity and Disease. Front. Immunol., 4, 2013, 98.
78. Ehlers, S., Schaible, U.E., The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front. Immunol., 3, 2012, 411.
79. Marakalala, M.J., et al. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat. Med. 22 (2016), 531–538.
80. Guirado, E., et al. Characterization of host and microbial determinants in individuals with latent tuberculosis infection using a human granuloma model. mBio, 6, 2015 e02537–14.
81. Kramnik, I., et al. Susceptibility to tuberculosis as a complex genetic trait: analysis using recombinant congenic strains of mice. Novartis Found. Symp. 217 (1998), 120–131.
82. Heitmann, L., et al. The IL-13/IL-4Ralpha axis is involved in tuberculosis-associated pathology. J. Pathol. 234 (2014), 338–350.
83. Cyktor, J.C., et al. IL-10 inhibits mature fibrotic granuloma formation during Mycobacterium tuberculosis infection. J. Immunol. 190 (2013), 2778–2790.
84. Pan, H., et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434 (2005), 767–772.
85. Williams, A., Orme, I.M., Animal models of tuberculosis: an overview. Microbiol. Spectr., 4, 2016, 10.1128/microbiolspec.TBTB2-0004-2015.
86. Flynn, J.L., et al. Immunology studies in non-human primate models of tuberculosis. Immunol. Rev. 264 (2015), 60–73.
87. Ernst, J.D., The immunological life cycle of tuberculosis. Nat. Rev. Immunol. 12 (2012), 581–591.
88. Perdomo, C., et al. Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis. mBio, 7, 2016 e01686–16.
89. Linderman, J.J., Kirschner, D.E., In silico models of M. tuberculosis infection provide a route to new therapies. Drug Discov. Today Dis. Models 15 (2015), 37–41.
90. Doryab, A., et al. Advances in pulmonary therapy and drug development: lung tissue engineering to lung-on-a-chip. Biotechnol. Adv. 34 (2016), 588–596.
91. Jambo, K.C., et al. AIDS patients have increased surfactant protein D but normal mannose binding lectin levels in lung fluid. Respir. Res., 8, 2007, 42.
92. Jambo, K.C., et al. Small alveolar macrophages are infected preferentially by HIV and exhibit impaired phagocytic function. Mucosal Immunol. 7 (2014), 1116–1126.
93. Diedrich, C.R., et al. HIV-1 and the Mycobacterium tuberculosis granuloma: a systematic review and meta-analysis. Tuberculosis (Edinb.) 98 (2016), 62–76.
94. Workineh, M., et al. Effect of helminths on immunity, clinical response and vaccination against tuberculosis: a review. Adv. J. Biol. Sci. Res. 1 (2013), 13–21.
95. O'Connor, G., et al. Sharpening nature's tools for efficient tuberculosis control: a review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery. Adv. Drug Deliv. Rev. 102 (2016), 33–54.
96. Crotty Alexander, L.E., Inflammatory diseases of the lung induced by conventional cigarette smoke: a review. Chest 148 (2015), 1307–1322.
97. Khalilullah, S.A., et al. Host genome polymorphisms and tuberculosis infection: what we have to say?. Egypt J. Chest Dis. Tuberc. 63 (2014), 173–185.
98. Azad, A.K., et al. Innate immune gene polymorphisms in tuberculosis. Infect. Immun. 80 (2012), 3343–3359.
99. Martiniano, S.L., et al. Nontuberculous mycobacterial infections in cystic fibrosis. Clin. Chest Med. 37 (2016), 83–96.
100. Poolman, E.M., Galvani, A.P., Evaluating candidate agents of selective pressure for cystic fibrosis. J. R. Soc. Interface 4 (2007), 91–98.